{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-024147","form_type":"8-K","ticker":"RNXT","cik":"0001574094","company_name":"RenovoRx, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.397233+00:00","generated_at":"2026-05-17T13:10:16.134685+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"RenovoRx Q2 2025 revenue $422k from RenovoCath; DMC recommends continue Phase III trial","bullets":["Q2 2025 revenue $422k from commercial RenovoCath sales, up from $0 in Q2 2024.","Cash $12.3M as of June 30, 2025; net loss $2.9M vs $2.4M YoY.","Independent DMC recommends continue Phase III TIGeR-PaC trial after second interim analysis; 95 patients randomized, 61 events.","13 cancer centers approved as customers (up from 5 in Q1); 4 have used device and placed repeat orders.","Hired Phil Stocton as Senior Director of Sales; launched PanTheR post-marketing registry study."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-024147","json":"https://secwatch.observer/filing/0001641172-25-024147.json","markdown":"https://secwatch.observer/filing/0001641172-25-024147.md","text":"https://secwatch.observer/filing/0001641172-25-024147.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574094/000164117225024147/0001641172-25-024147-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574094/000164117225024147/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:10:16.134685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}